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Abstract 
Background 
Atrial fibrillation is very common in people aged 65 or older. This condition increases the 
risk of death, congestive heart failure and thromboembolic conditions. Many patients with 
atrial fibrillation are asymptomatic and a cerebrovascular accident (CVA) is often the first 
clinical presentation. Guidelines concerning the prevention of CVA recommend monitoring 
the heart rate in patients aged 65 or older. Recently, the MyDiagnostick (Applied Biomedical 
Systems BV, Maastricht, The Netherlands) was introduced as a new screening tool which 
might serve as an alternative for the less accurate pulse palpation. This study was designed to 
explore the diagnostic accuracy of the MyDiagnostick for the detection of atrial fibrillation. 
Methods 
A phase II diagnostic accuracy study in a convenience sample of 191 subjects recruited in 
primary care. The majority of participants were patients with a known history of atrial 
fibrillation (n = 161). Readings of the MyDiagnostick were compared with 
electrocardiographic recordings. Sensitivity and specificity and their 95% confidence interval 
were calculated using 2x2 tables. 
Results 
A prevalence of 54% for an atrial fibrillation rhythm was found in the study population at the 
moment of the study. A combination of three measurements with the MyDiagnostick for each 
patient showed a sensitivity of 94% (95% CI 87–98) and a specificity of 93% (95% CI 85–
97). 
Conclusion 
The MyDiagnostick is an easy-to-use device that showed a good diagnostic accuracy with a 
high sensitivity and specificity for atrial fibrillation in a convenience sample in primary care. 
Future research is needed to determine the place of the MyDiagnostick in possible screening 
or case-finding strategies for atrial fibrillation. 
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Background 
Atrial fibrillation is currently the second most frequently occurring cardiac arrhythmia in 
clinical practice (after extrasystole). Its prevalence is estimated around 0.4 – 1.0% in the 
general population, increasing with age, up to 5.0 – 6.0 in those aged 65 or older and 8.0% in 
subjects aged 80 or older[1]. 
More than 30% of patients with atrial fibrillation are asymptomatic. Furthermore, this 
condition increases the risk of death, congestive heart failure and thromboembolic conditions 
[2,3]. The risk of cerebrovascular accident (CVA) even increases fivefold in case of atrial 
fibrillation and CVA is often the first clinical presentation of atrial fibrillation. Moreover, the 
risk for CVA increases with increasing age; from 9.9% in patients between 70–79 years to 
24% in the group of patients between 80 – 89 years [4-6]. 
The current European guidelines on atrial fibrillation emphasize the importance to start 
anticoagulation in order to decrease the risk of CVA [6]. In order to assess this risk, the 
CHADS2 score is used, along with the more recent and more accurate CHA2DS2VASc score 
[7,8]. Therefore, the high prevalence of atrial fibrillation, the potentially serious 
consequences of the condition, the presence of effective therapy and the minimal impact of 
treatment on the quality of life of the patient ensure that atrial fibrillation is a condition for 
which screening can or should be done [9]. 
Guidelines concerning the prevention of CVA recommend monitoring the heart rate in 
patients aged 65 or older, followed by electrocardiogram (ECG) monitoring in case of an 
irregular rhythm [6,10]. Palpation of the pulse, to monitor the heart rate, has a good 
sensitivity but a low specificity, making this a useful method of ruling out atrial fibrillation 
but a less good method of confirming it11. Recently, the MyDiagnostick (Applied Biomedical 
Systems BV, Maastricht, The Netherlands) [11] was introduced as a new screening tool and 
an alternative for the less accurate pulse palpation. This device has the form of a rod with a 
metal handle on both ends. There are electrodes in these handles making it possible to record 
a single-lead ECG (Figure 1). This new screening technique would facilitate home screening 
and increase the likelihood of detection of asymptomatic atrial fibrillation. 
Figure 1 The MyDiagnostick device. 
Therefore, this study was designed to explore the diagnostic accuracy of the MyDiagnostick 
for the detection of atrial fibrillation. 
Methods 
Study population 
Participating general practitioners were asked to invite patients with known, paroxysmal or 
chronic atrial fibrillation to participate in the study. Furthermore, this convenience sample 
was added up with subjects without a history of atrial fibrillation. With the probability of 
finding a false positive result of 5% or less (α = 0.05), an estimated prevalence of atrial 
fibrillation of 50% in the study population, an expected sensitivity and specificity of 95% and 
a confidence interval of 4%, a sample size of 160 subjects was needed [12]. To end up with a 
prevalence of atrial fibrillation of at least 50% at the moment of the study the vast majority of 
the invited patients were people with a known history of atrial fibrillation (161/191) and only 
30 people without a history of atrial fibrillation. The patients who were willing to take part in 
the survey were given an appointment for an examination by the research team in their own 
general practice centre. Before participating in the study, all patients signed an informed 
consent. The study was approved by the ethical review board of the Medical Faculty of the 
Catholic University of Leuven, Belgium (no ML 10464). Patients wearing a pacemaker were 
excluded if the pacemaker was configured in active pacing mode. 
Clinical characteristics were registered by the researcher (SS, KT, BT or DL). The body mass 
index was calculated, the blood pressure measured and a limited number of comorbidities 
extracted from the electronic medical record. The presence of diabetes mellitus type II, 
arterial hypertension and peripheral arterial illness and a history of coronary heart disease and 
transient ischaemic attack or CVA was reported and the CHA2DS2VASc score for each 
participant calculated. The intake of platelet aggregation inhibitors or anticoagulants 
(warfarin or new oral anticoagulants) was registered. 
A trial fibrillation 
Each participant was tested with the MyDiagnostick (Applied Biomedical Systems BV, 
Maastricht, The Netherlands) [11] by a single researcher who was not blinded for the medical 
history of the patient. This device has the form of a rod with a metal handle on both ends. In 
these handles electrodes make it possible to record a single-lead ECG that is analyzed 
automatically. The patient was asked to grasp the device by both handles. After one minute 
the ECG lead was analysed and LED indicators gave a red or green signal that could be 
interpreted as the presence or absence of atrial fibrillation. Three consecutive recordings with 
the MyDiagnostick with a 1–2 minute interval were done. Figure 2 shows single-lead ECGs 
provided by the MyDiagnostick. The MyDiagnostick has a storage capacity of 140 recordings 
of 50 – 70 seconds. 
Figure 2 Single-lead ECGs provided by the MyDiagnostick (sinus rhythm and atrial 
fibrillation). 
The method of detection of AF in the MyDiagnostick is based on the measurement of R-R 
interval irregularity. Prior AF detection, the acquired ECG (1 minute) is pre-processed and R-
waves are detected. From all detected R-wave annotations, R-R intervals are computed and 
used as an input for AF detection. The AF algorithm calculates an overall AF score based on 
a base rhythm-, periodicity- and variability score. The base rhythm score is based on a normal 
sinus rhythm state-machine chaining normal R-R intervals, including occasional premature 
intervals and short runs of tachycardia. Creation of long chains reflects a fit of the sinus 
rhythm state-model, lowering the probability of AF. The periodicity and variability scores are 
based on the R-R autocorrelation function. Periodicity of R-R interval patterns will generate 
multiple correlation peaks, whereas R-R interval irregularity will lower correlation at only a 
small shift. The overall AF score is obtained by linear combination of all scores and 
compared to a threshold, producing a dichotomous result (AF/no AF). 
Afterwards a 12-lead electrocardiogram (ECG) (gold standard) was carried out once by the 
same researcher. The ECGs were done using digital machines (HeartScreen 80 G-L 
(MediSafe Ltd, Winchester, United Kingdom), Welch Allyn CP 50 (Welch Allyn, New York, 
USA), Nihon Kohden Cardiofax S 1250 (Nihon Kohden, Tokyo, Japan) or Schiller AT101 
(Schiller AG, Baar, Switzerland)) and the data were immediately printed. The ECGs were 
analyzed off-line on the basis of the Minnesota Code Classification System for 
Electrocardiographic Findings [13] (code 8-3-1) by an experienced cardiologist (WM), 
blinded for the software interpretation and the results from the MyDiagnostick. 
The readings of the MyDiagnostick were compared with the electrocardiographic recording. 
The overall three measurements on the MyDiagnostick were viewed for each patient. A green 
light three times was interpreted as a negative result and a red light three times as a positive 
result. The non-uniform results of the MyDiagnostick were interpreted in favour of the most 
common outcome (i.e. 2x red and 1x green was interpreted as a positive result, while 1x red 
and 2x green was interpreted as a negative result). 
Statistical analysis 
Sensitivity and specificity and their 95% confidence interval were calculated using 2x2 tables 
(MedCalc® 11.6.0.0 (Mariakerke, Belgium)). The positive and negative predictive values 
were then estimated based on an expected prevalence of atrial fibrillation of 6% in the 
population aged 65 or older. 
Results 
A total of 191 subjects participated in this study of which 91 (48%) women. The mean age of 
the participants was 74.6 ± 9.7 years (range 50 – 99 years). In total 30 participants without a 
history of atrial fibrillation (all in sinus rhythm on ECG) and 161 participants that were 
known to have paroxysmal or chronic atrial fibrillation were included (Figure 3). Of these 
latter subjects, 103 showed atrial fibrillation on their ECG at the moment of the study. Thus, 
a prevalence of 54% for an atrial fibrillation rhythm was found in the study population. Table 
1 shows the patient characteristics according to the presence of atrial fibrillation. A 
pacemaker was present in 17 participants, in 10 patients the pacemaker was active at the 
moment of the ECG recording and they were therefore excluded from further analysis. The 
analysis was continued with 181 participants (prevalence of atrial fibrillation, 53%). 
Figure 3 Flow chart of study participants. 
Table 1 Characteristics of the study population (n = 191) 
 Atrial fibrillation present Atrial fibrillation absent 
(n = 103) (n = 88) 
Age, mean ± SD 77 ± 8 71 ± 11 
Male gender, n (%) 57 (55.3) 43 (51.1) 
BMI, mean ± SD 27.7 ± 6.9 25.9 ± 6.5 
Systolic blood pressure, mean ± SD 130 ± 19 130 ± 18 
Diastolic blood pressure, mean ± SD 75 ± 14 75 ± 10 
CHA2DS2VASC score, median (IQR) 3 (2 – 4) 3 (2 – 3) 
Comorbidity   
Diabetes mellitus type II, n (%) 26 (25.2) 15 (17.0) 
Arterial hypertension, n (%) 94 (91.3) 62 (70.5) 
Coronary heart disease, n (%) 9 (8.7) 16 (18.2) 
TIA or CVA, n (%) 17 (16.5) 4 (4 .5) 
Peripheral arterial illness, n (%) 4 (3.9) 4 (4.5) 
Anticoagulation   
No anticoagulation, n (%) 0 (0) 22 (25.0) 
Platelet aggregation inhibitor, n (%) 6 (5.8) 24 (27.3) 
Warfarin, n (%) 69 (67.0) 30 (34.1) 
New oral anticoagulants, n (%) 28 (27.2) 12 (13.6) 
SD: standard deviation; IQR: inter-quartile range; TIA : transient ischaemic attack : CVA : 
cerebro-vascular accident. 
The MyDiagnostick showed a positive result in 96 participants and a negative result in 85 
subjects (Table 2). No unsuccessful attempts were reported. In the event of a uniform result 
(n = 166, 92%) the diagnosis was correct in 96% of cases (seven misdiagnoses, four false 
positives and three false negatives). A total of 15 participants showed non-uniform results 
(nine positive results, and six negative results), in which 10 participants were interpreted 
correctly (seven true positives and three true negatives) and five were misinterpreted. On the 
basis of these results sensitivity for the MyDiagnostick of 94% (95% CI 87–98) and a 
specificity of 93% (95% CI 85–97) was obtained. Based on an expected prevalence of 6% in 
the population aged 65 or older a positive predictive value of 45% (95% CI 24 – 68) and a 
negative predictive value of 99% (95% CI 97–100) were estimated. 
Table 2 2x2 table to calculate the diagnostic accuracy of the MyDiagnostick 
 Atrial fibrillation present Atrial fibrillation absent Total 
MyDiagnostick positive result 90 6 96 
MyDiagnostick negative result 6 79 85 
Total 96 85 181 
Discussion 
In this study of a convenience sample in primary care, the MyDiagnostick was able to 
accurately set the diagnosis of atrial fibrillation with a high sensitivity and specificity. The 
sensitivity measures the proportion of actual positives that have been correctly identified and 
the specificity measures the proportion of the actual negatives that have been appropriately 
recognized as such. These two measures are closely related to the concepts of type I (a test 
that shows a patient to have a disease when in fact the patient does not have the disease) and 
type II (a test that shows a patient not to have a disease when the patient does have the 
disease) errors. A perfect diagnostic test would be 100% sensitive (no false negatives) and 
100% specific (no false positives). However, in a low prevalence setting like primary care 
and for possible screening purposes the sensitivity of a test, the capacity to rule out the 
disease, could be considered as the most important measure. 
The results for the MyDiagnostick are in line with the diagnostic accuracy found for other 
screening methods and devices. Pulse palpation to detect an irregular heartbeat gave a high 
sensitivity (87% – 97%) but a moderate to low specificity (71% – 81%) [14,15]. Although the 
specificity could possibly be improved by continued pulse registration, but at the cost of 
decreasing sensitivity. The Microlife BP monitor (Microlife Corporation, Taipei, Taiwan), a 
modified sphygmomanometer that records pulse intervals, gave a sensitivity of 100% and a 
specificity of 90% (95% CI 87 – 92) when multiple measurements were carried out [16]. 
Another study that also used a modified sphygmomanometer showed a sensitivity of 95% 
(95% CI 93 – 98) and specificity of 86% (95% CI 84–98) in a single measurement and a 
sensitivity of 97% (95% CI 91 – 99) and specificity of 89% (95% CI 85 – 92) on 3 
measurements [17]. A finger probe that registered a pulse wave pattern for 30 seconds gave a 
sensitivity of 100% and a specificity of 91% [18]. Two studies, similar to the current study, 
also used a device that registered a single-lead ECG in which the interpretation was done 
afterwards by a primary care physician [17,19]. Somerville et al. found a sensitivity of 96% 
(95% CI 80 – 100) and a specificity of 98% (95% CI 91 – 100) [17], and Mant et al. found a 
sensitivity of 85% (95% CI 79 – 91) and a specificity of 86% (95% CI 85 – 88) with the use 
of a thoracic lead and a sensitivity of 83% (95% CI 75 – 89) and a specificity of 89% (95% 
CI 87 – 90) with the use of a peripheral lead [19]. The latter sensitivities and specificities 
were moderate primarily due to the varying interpretation of ECGs by primary care 
physicians. By contrast, the advantage of the MyDiagnostick is the absence of an 
interpretation bias. 
This study was a phase II diagnostic study investigating the accuracy of the MyDiagnostick 
in a convenience sample of healthy people and people with a history of atrial fibrillation. 
However, before a clinical recommendation on the use of the MyDiagnostick in every day 
clinical practice can be given, a phase III diagnostic study has to be performed, determining 
the clinical consequences of introducing the MyDiagnostick through a randomised trial. The 
place of the MyDiagnostick in possible future screening programs for atrial fibrillation 
therefore remains to be determined. The use of the MyDiagnostick seems much more 
practical than electrocardiographic monitoring at home. It involves no skin electrodes or 
wires and the use of the device does not require any experience or medical knowledge. 
Furthermore, using the MyDiagnostick is faster and cheaper. The MyDiagnostick also has an 
additional advantage in comparison with a blood pressure monitor that detects an irregular 
pulse, since every recording is registered and the single-lead ECGs can be consulted later on 
to confirm the red lights that the patient detected. 
In terms of user friendliness, this screening tool is easily manageable in the population aged 
65 or older. The patient only needs to hold the ends of the rod with both hands. The unit goes 
on automatically, so that a visual limitation cannot be a restricting factor. Furthermore, 
holding with the palm of the hand up or down, holding it lightly or firmly, trembling and 
physical activity during use do not seem to influence the accuracy and uniformity of the 
results. 
In addition to detecting paroxysmal atrial fibrillation and initiating the necessary treatment, 
the following advantages of future use could be hypothesized: following up on the response 
to electroconversion and medical treatment, improving compliance with therapy and 
potentially decreasing medical costs (by means of the prevention of ischemic CVA). 
Strengths and limitations 
This is the first study investigating the diagnostic accuracy of the MyDiagnostick in primary 
care. High sensitivities and specificities were obtained in the study population, making this 
easy-to-use device a possible candidate to implement in future screening or case-finding 
programs for atrial fibrillation. However, a few limitations of the current study should be 
mentioned. First, a prevalence of atrial fibrillation of 6% was assumed in subjects aged 65 
and older. However, a variety of prevalence figures is found in literature and is mainly the 
result of differences in the study population, the methods used (Holter, serial ECGs …) and 
the duration of ECG recording. Second, several ECG devices were used as the gold standard 
instead of one standardized device. Third, the possible place of the MyDiagnostick in a 
screening or case-finding strategy was not determined with the current study, nor was a cost-
benefit analysis of a screening or case-finding strategy with the MyDiagnostick done. And 
fourth, because the study population was a convenience sample extrapolation of these results 
to the general population should be made with caution. Furthermore, investigations 
concerning the reliability of the MyDiagnostick for other arrhythmias and test-retest 
reliability must still be done. 
Conclusion 
The MyDiagnostick is an easy-to-use device that showed a good diagnostic accuracy with a 
high sensitivity and specificity for atrial fibrillation in a convenience sample in primary care. 
Future research is needed to determine the place of the MyDiagnostick in possible screening 
or case-finding strategies for atrial fibrillation. 
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